We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bupropion in Helping Adults Stop Smoking

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00534001
Recruitment Status : Completed
First Posted : September 24, 2007
Results First Posted : May 30, 2017
Last Update Posted : May 30, 2017
Information provided by (Responsible Party):
Roswell Park Cancer Institute

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Other
Conditions: Bladder Cancer
Cervical Cancer
Esophageal Cancer
Gastric Cancer
Head and Neck Cancer
Kidney Cancer
Liver Cancer
Lung Cancer
Pancreatic Cancer
Tobacco Use Disorder
Interventions: Drug: bupropion hydrochloride
Other: placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
1-week Run In (Standard) No text entered.
4-week Run-in (Extended) No text entered.

Participant Flow:   Overall Study
    1-week Run In (Standard)   4-week Run-in (Extended)
STARTED   48   47 
COMPLETED   43   43 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Arm I (1-week run-in)

Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.

bupropion hydrochloride: Given orally

placebo: Given orally

Arm II (4-week run-in)

Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.

bupropion hydrochloride: Given orally

Total Total of all reporting groups

Baseline Measures
   Arm I (1-week run-in)   Arm II (4-week run-in)   Total 
Overall Participants Analyzed 
[Units: Participants]
 48   47   95 
[Units: Years]
Mean (Standard Deviation)
 46.7  (9.3)   45.8  (10.1)   46  (10) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      26  54.2%      24  51.1%      50  52.6% 
Male      22  45.8%      23  48.9%      45  47.4% 
Race/Ethnicity, Customized 
[Units: Participants]
Count of Participants
Racial/Ethnic Minority   5   4   9 
White/Not Hispanic   43   43   86 
Region of Enrollment 
[Units: Participants]
Count of Participants
United States   48   47   95 
Cigarettes Smoked Per Day (CPD) 
[Units: CPD]
Mean (Standard Deviation)
 22.0  (6.0)   23.4  (7.9)   23  (7) 

  Outcome Measures

1.  Primary:   Prequit Change in Cigarettes Per Day   [ Time Frame: 3-Week PreQuit Drug Manipulation Phase ]

2.  Secondary:   Abstinence   [ Time Frame: 4 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Martin Mahoney
Organization: Roswell Park Cancer Institute
phone: 716-845-2300
e-mail: martin.mahoney@roswellpark.org

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00534001     History of Changes
Other Study ID Numbers: CDR0000565103
I 57805 ( Other Identifier: Roswell Park Cancer Institute )
First Submitted: September 20, 2007
First Posted: September 24, 2007
Results First Submitted: February 20, 2017
Results First Posted: May 30, 2017
Last Update Posted: May 30, 2017